Geode Capital Management Boosted By $359,079 Its Antares Pharma (ATRS) Holding; Amarin PLC Has 1.22 Sentiment

March 21, 2018 - By Michael Collier

Geode Capital Management Llc increased Antares Pharma Inc (ATRS) stake by 10.06% reported in 2017Q3 SEC filing. Geode Capital Management Llc acquired 119,693 shares as Antares Pharma Inc (ATRS)’s stock 0.00%. The Geode Capital Management Llc holds 1.31 million shares with $4.24 million value, up from 1.19M last quarter. Antares Pharma Inc now has $352.52 million valuation. It closed at $2.25 lastly. It is down 207.14% since March 21, 2017 and is uptrending. It has outperformed by 190.44% the S&P500.

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company has market cap of $1.03 billion. The companyÂ’s lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It currently has negative earnings. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels.

The stock decreased 1.27% or $0.0407 during the last trading session, reaching $3.1593. About 3.70 million shares traded or 76.84% up from the average. Amarin Corporation plc (AMRN) has risen 76.19% since March 21, 2017 and is uptrending. It has outperformed by 59.49% the S&P500.

Ratings analysis reveals 100% of Amarin’s analysts are positive. Out of 2 Wall Street analysts rating Amarin, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5.0 while the high is $6.0. The stock’s average target of $5.50 is 74.09% above today’s ($3.1593) share price. AMRN was included in 2 notes of analysts from October 5, 2016. Cantor Fitzgerald initiated the stock with “Buy” rating in Wednesday, October 5 report. As per Wednesday, October 19, the company rating was initiated by Citigroup.

Analysts await Amarin Corporation plc (NASDAQ:AMRN) to report earnings on May, 2. They expect $-0.06 EPS, up 25.00% or $0.02 from last year’s $-0.08 per share. After $-0.08 actual EPS reported by Amarin Corporation plc for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

Consonance Capital Management Lp holds 9.54% of its portfolio in Amarin Corporation plc for 24.65 million shares. Oracle Investment Management Inc owns 6.30 million shares or 3.62% of their US portfolio. Moreover, Healthcare Value Capital Llc has 3.15% invested in the company for 450,000 shares. The New York-based Broadfin Capital Llc has invested 0.85% in the stock. University Of Notre Dame Du Lac, a Indiana-based fund reported 803,888 shares.

Since January 1, 0001, it had 0 insider purchases, and 7 insider sales for $2.04 million activity.

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 12 analyst reports since March 9, 2016 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Wednesday, November 8. On Wednesday, March 14 the stock rating was maintained by H.C. Wainwright with “Buy”. As per Tuesday, July 25, the company rating was maintained by Piper Jaffray. The firm has “Buy” rating by H.C. Wainwright given on Monday, October 23. H.C. Wainwright initiated Antares Pharma, Inc. (NASDAQ:ATRS) rating on Friday, September 8. H.C. Wainwright has “Buy” rating and $5.0 target. The rating was initiated by H.C. Wainwright with “Buy” on Friday, June 23. The rating was maintained by Piper Jaffray on Monday, October 23 with “Buy”. The firm has “Buy” rating by Jefferies given on Monday, August 7. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) has “Buy” rating given on Tuesday, October 10 by Jefferies. The stock has “Buy” rating by Jefferies on Wednesday, March 9.

Investors sentiment decreased to 1.16 in 2017 Q3. Its down 0.13, from 1.29 in 2017Q2. It dropped, as 11 investors sold ATRS shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 53.56 million shares or 0.15% less from 53.64 million shares in 2017Q2 were reported. Two Sigma Securities Ltd Co, New York-based fund reported 16,633 shares. Carl Domino has 32,500 shares. Guggenheim Cap Limited Co holds 408,944 shares or 0% of its portfolio. Moreover, Tiaa Cref Limited Liability Co has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS). State Common Retirement Fund holds 0% or 121,500 shares in its portfolio. Moreover, Alliancebernstein LP has 0% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 36,900 shares. Bnp Paribas Arbitrage Sa reported 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Natixis owns 17,901 shares or 0% of their US portfolio. Rhumbline Advisers reported 150,288 shares or 0% of all its holdings. Raymond James accumulated 11,323 shares. Avenir Corp owns 351,685 shares. Oppenheimer And Communication has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Ballentine Prns Ltd, a Massachusetts-based fund reported 100,000 shares. State Street holds 0% or 2.64 million shares. Broadfin Capital Ltd has invested 1.54% in Antares Pharma, Inc. (NASDAQ:ATRS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: